The Wee1 inhibitor adavosertib shows activity in recurrent uterine serous carcinoma, but the drug’s tolerability remains a ...

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in ...

Following promising phase 1 data, ISB 2001 has gained fast track designation from the FDA for the treatment of ...

The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in ...

A transformative milestone in cancer care has arrived in Central New Jersey with the reopening of the John Theurer Cancer ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

Fengting Yan, MD, PhD, discusses the challenge of balancing clinical judgment with genomic test results in breast cancer.

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell ...

Jyoti Srivastava, PhD, discusses a study investigating methods to boost inhibitor function in advanced melanoma.

David Polsky, MD, discussed a study showing ctDNA levels before melanoma treatment strongly predict recurrence and its speed, ...

Panelists discuss how the decision to initiate cytoreductive therapy in polycythemia vera (PV) is driven by high-risk ...

Panelists discuss how frequent phlebotomy requirements—typically more than 4 to 6 times per year—serve as a marker of inadequate disease control in polycythemia vera (PV), prompting consideration of ...